Drug Guidance for Subsidy 02/09/2019 Endothelin receptor antagonists for treating pulmonary arterial hypertension The Ministry of Health’s Drug Advisory Committee has recommended: Ambrisentan 5 mg and 10 mg ... See all × 02/09/2019 Endothelin receptor antagonists for treating pulmonary arterial hypertension The Ministry of Health’s Drug Advisory Committee has recommended: Ambrisentan 5 mg and 10 mg tablets for treating adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies: Idiopathic PAH; Heritable or familial PAH; PAH associated with connective tissue disease; Anorexigen-induced PAH; or PAH associated with HIV infection. Subsidy status RAmbrisentan 5 mg and 10 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. NRMAF assistance does not apply to bosentan 62.5 mg and 125 mg tablets, and macitentan 10 mg tablet.
Post Marketing Information DHCPL 09/11/2020 Concomitant use of Opsumit® (macitentan) Film-Coated Tablet 10mg with dual moderate CYP3A4/CYP2C9 inhibitors that could result in an increase in exposure to Opsumit® PMG 25/06/2015 PATIENT MEDICATION GUIDE: OPSUMIT® Macitentan tablets
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Film Coated 10 mg Changi General Hospital National Heart Centre National University Hospital Singapore General Hospital